Vetera® GoldXP

Influenza (Clade 1 and Clade 2), Herpes (EHV-1 and EHV-4), Eastern & Western Encephalomyelitis, West Nile Virus, Tetanus

Overview

  • Protects against EIV, EHV (EHV-1 and EHV-4), EEE, WEE, Tetanus and West Nile Virus in 1 mL dose, offering the ultimate in convenience and protection
  • At least 6 month duration of immunity against equine influenza (Ohio/03)
  • At least 12 month WNV duration of immunity
  • Safe for use in horses as young as 4 months of age, including pregnant mares
  • Contains equine origin 2005 West Nile Virus isolate (E159™) - the strain most likely to infect horses today
  • Ohio/03 (Clade 1), Richmond/07 (Clade 2) and Kentucky/95 equine influenza strains as recommended by the Expert Surveillance Panel on Equine Influenza
  • Unique purification process and adjuvant formulation minimizes non-relevant protein presented to the immune system
  • Available in single dose pre-filled syringes or color-coded 10 dose vials

Features

  • Contains 9 antigens in one vaccine 
  • Includes Ohio/03 (Clade 1), Kentucky/95, and Richmond/07 (Clade 2) equine influenza strains
  • Contains EHV-1 and EHV-4
  • Includes a unique North American Equine E159™ West Nile Virus strain
  • Incorporates the Carbimmune® adjuvant formulation
  • Ultrafil® purification technology
  • At least 6 month duration of immunity against equine influenza (Ohio/03) 
  • At least 12 month WNV duration of immunity
  • Safe for use in horses as young as 4 months of age, including pregnant mares

Benefits

  • Unique 8-way protection in one vaccine
  • Contains relevant influenza viruses, including Clade 1 and Clade 2 strains
  • Protection against both EIV and EHV
  • Contains equine origin 2005 West Nile Virus isolate (E159™) - the strain most likely to infect horses today.
  • Dual phase system delivers both rapid and long-lasting immunity
  • Safe, high-quality vaccines

Shake well before use.  Using aseptic technique, inoculate horses intramuscularly with a 1 mL dose. Administer a second 1 mL dose intramuscularly in 3-4 weeks using a different injection site. Revaccinate annually and prior to anticipated exposure with a single 1 mL intramuscular dose.

This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy in normal, healthy, immunocompetent animals.  This level of performance may be affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies, or impaired immunological competency.  These factors should be considered by the user when evaluating product performance or freedom from reactions.

Product Resources

Technical Assistance

  • Boehringer Ingelheim Vetmedica, Inc.

    Equine Division

    3902 Gene Field Road
    St. Joseph, Missouri 64506

    • Phone 866-638-2226
    • Fax 816-676-4326